Drugs Targeting BRAF
- Mekinist (trametinib) plus Taflinar (dabrafenib) – approved in combination for stage 4 NSCLC patients with the BRAF V600E change as detected by a biomarker test.
- Braftovi (encorafenib) plus Mektovi (binimetinib) – approved for adults with stage 4 metastatic NSCLC with a BRAF V600E change as detected by an FDA-approved biomarker test.